Podcasts about Leukemia

During Alisha Harper's pregnancy, she was told that there was a 60 percent chance that her son would be born with Down Syndrome. That statement turned out to be a correct one as Chase was born in December of 2016 with this illness and by the time Chase was 4 years old, Alisha saw that his Down Syndrome was manageable. One month after feeling as good as possible about how Chase was doing, he developed a body rash which turned out to be a symptom of Acute Lymphoblastic Leukemia. Despite having this 1-2 punch thrown at him, Chase is doing well as he is now 9 years old and living his best life possible. 

In this week's episode, Blood editor Dr. Philippe Armand interviews Drs. Manali Kamdar and Nancy L. Bartlett on their latest review article published in Blood titled “From breakthroughs to blueprints: evolving evidence and future directions in relapsed and refractory large B-cell lymphoma”. They discuss the how the advent of chimeric antigen receptor T cells, antibody-drug conjugates, and bispecific antibodies all show major increases in efficacy over legacy chemotherapy-based regimens. They also share their insights on how to transform treatment paradigms in light of these breakthroughs.

In this Review series episode, Blood associate editor Dr. Diane Krause interviews contributing authors from the Review Series on Clonal tracking in Hematopoiesis published in volume 147 issue 23 of Blood. Dr. Alejo E. Rodriguez-Fraticelli speaks to the development of his paper, "Clonal tracing of blood stem cells across mouse and human lifespans”, which provides a detailed overview of the experimental approaches that make clonal analysis possible, and which approaches are most appropriate to use to address specific questions. Dr. Shalin H. Naik speaks about how different clonal tracking approaches have been used to address the central question of clonal fate specification of stem and progenitor cells to specific lineages in “The evolution of hematopoietic models through a clonal lens”. Finally, Dr. Federico Gaiti speaks about “Methylation-based lineage tracing in cancer”, which takes these ideas into the context of cancer, focusing on how DNA methylation can be used to reconstruct clonal relationships.  

On Saturday night, folks will gather at the Sagamore Pendry to celebrate the Visionary of The Year for Blood Cancer United, which you might know was the Leukemia and Lymphoma Society. Former MLB outfielder and Towson alum Casper Wells is pitching in and batting cleanup in trying to raise funds and awareness and visits with Nestor here for some current Orioles chatter and ways you can help cancer patients. The post Former MLBer Casper Wells returns to talk blood cancer and Orioles finding bats and more runs first appeared on Baltimore Positive WNST.

What if your body already has everything it needs to heal and unresolved trauma is the only thing standing in the way?In this episode of What Happens in Vagus, Dr. Stephanie Canestraro sits down with Peter McLaughlin, a certified hypnotherapist who put his chronic lymphocytic leukemia into remission in 2003, without chemotherapy. Peter's journey began in the wreckage of a life running on pure adrenaline: a demanding Wall Street career, a two-hour daily commute, three young children, and an office one block from Ground Zero on September 11th. When his body finally gave out, his leukemia diagnosis became the catalyst that set him on a path toward subconscious healing, hypnotherapy, and a complete understanding of the mind-body connection.Together, Peter and Dr. Stephanie explore one of the most overlooked truths in chronic illness: that emotional trauma, including small, seemingly insignificant moments from childhood, gets stored in the subconscious mind and continues to drive the body's stress response for decades. Because the subconscious has no concept of time, a humiliating moment in third grade or a cry left unanswered in a crib can still be activating a fight-or-flight response in your body today. This chronic activation of the autonomic nervous system suppresses immunity, disrupts hormones, stalls digestion, and creates the environment in which disease takes root.Dr. Stephanie also shares her own healing journey from a Lyme disease and Bartonella infection that attacked her nervous system and went undiagnosed for over a decade, to the functional medicine interventions, precious metal IVs, and reconnection with her body's inner wisdom that finally brought her back. Together they connect the dots between nervous system dysregulation, frequency medicine, and the extraordinary capacity of the human body to heal when given the right tools.✦ In this episode:• How chronic stress and emotional trauma directly contribute to serious illness• Why childhood events your conscious mind has "forgotten" are still running your nervous system• What hypnotherapy actually does and how it clears emotional toxins from the subconscious• Why you cannot heal in fight-or-flight mode and how to shift into rest-and-digest• How cortisol signals your body to hold onto fat• 432 Hz healing music, binaural beats, and frequencies that regulate the nervous system• Applied kinesiology, muscle testing, and pendulum work as tools for inner wisdom• Peter's work with professional athletes and how childhood trauma shows up on the field• Precious metals (gold, silver, platinum) and their role in healing chronic infection• The placebo effect as proof of the mind's power to heal the body✦ Find Peter McLaughlin:Website & healing tracks: blueskyhypnosis.comYouTube: @blueskyhypnosis✦ About Dr. Stephanie Canestraro:Dr. Stephanie is a chiropractor, functional medicine practitioner, and chronic illness survivor. Her practice and this podcast are rooted in one belief: that the body is designed to heal, and that the vagus nerve is the master key to making that happen.Let us know your thoughts on this episode hereFor any further information, feel free to email us at info@vagusclinic.com.  Our team is happy to help.  We offer 20-minute complimentary health calls, and you can sign up for one here.

Message us!In this episode of Whitley Penn Talks, host Emily Landry is joined by Dr. Paul Bowman, longtime pediatric oncologist and co-chair of Leukemia Texas, who shares clear and hopeful insights on what leukemia is and how far treatment for the disease has come. Alongside him, Ashley Oviedo opens up about her daughter, Perry's, diagnosis, offering an honest and emotional look at the fear, uncertainty, and strength that define a family's journey through cancer.Together, they highlight the critical role organizations like Leukemia Texas play in supporting families medically, financially, and emotionally through their most challenging times. From the first signs of illness to the importance of accepting help and holding onto hope, this conversation is a reminder that no one should fight cancer alone.Fill out this form to have new episodes sent right to your inbox! Follow Whitley Penn on LinkedIn, Instagram, Facebook, and X for more industry insights and thought leadership!

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Johnny Mahlangu and Joseph Rocco on their articles published in volume 147 issue 9 of Blood.  Dr. Mahlangu discusses study details and next steps from "Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial" which shows that bleeding was reduced by 93% with subcutaneous marstacimab. Dr. Rocco shares the development behind "CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis", and the insights gained from measuring a new surrogate marker of IFN-γ activity predicting severity and mortality.

Yale Cancer Center Director Dr. Eric Winer speaks with Dr. Max Stahl about how much is now known on the biology of leukemia in some patients, rare disease sub-types and targeting with specific therapies. Yale Cancer Center Visit: https://medicine.yale.edu/cancer/ Email: canceranswers@yale.edu Call 203-785-4095

 In this episode, Blood deputy editor Dr. Helen Heslop interviews contributing  authors from the Blood review series on hemophagocytic lymphohistiocytosis. Drs. Nancy Berliner and Joanne Hsu join to provide insight on their paper, “Hemophagocytic lymphohistiocytosis in adults” discussing the importance of prompt diagnosis and treatment in this high-mortality disorder, and highlight emerging agents designed to modulate disease progression. Drs. Carl Allen and Bethany Verkamp reimagine diagnostic criteria through a threshold model in “Pediatric hemophagocytic lyphohistiocytosis: current conceptualization, diagnosis, and treatment”, in order to provide individualized therapies with the goal of addressing the combined influence of genetic susceptibility and environmental triggers.

This accredited continuing education program is supported by an educational grant from Blueprint Medicine. It provides timely and practical education on systemic mastocytosis (SM). To obtain CME credit, visit https://checkrare.com/learning/p-systemic-mastocytosis-recognition-diagnosis-and-clinical-management/SM is a rare, chronic disorder driven by aberrant mast cell accumulation across multiple organ systems. Although diagnostic criteria are well established, a recent natural history study found that the average time to diagnosis is nearly five years. This prolonged delay—largely due to limited awareness of SM and its early symptoms—often results in unnecessary disease progression and inappropriate treatment. To address this clinical gap, this activity, led by Daniel J. DeAngelo, MD, PhD, Chief, Division of Leukemia at the Dana-Farber Cancer Institute, Harvard Medical School, in Boston, MA, provides an overview of the early signs and symptoms of SM, outlines the appropriate diagnostic criteria and tools, and reinforces the importance of timely referral and testing for these patients to be properly managed. Led by a clinical expert with experience diagnosing and treating patients with SM, this 45-minute CME program will highlight early signs of SM, outline diagnostic criteria and tools, and reinforce the importance of timely referral/testing. Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hematology, dermatology, gastroenterology, immunology, and family practice. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the early symptoms of systemic mastocytosis and its clinical relevance.Apply best practices to diagnose systemic mastocytosis more efficiently.FacultyDaniel J. DeAngelo, MD, PhDChief, Division of LeukemiaDana-Farber Cancer Institute,Harvard Medical SchoolBoston, MADisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. DeAngelo discloses the following relevant financial relationships with ineligible companies:Consultant: Amgen, Autolos, Blueprint Medicines, Incyte, Jazz, Novartis, Pfizer, and Takeda Research Support: AbbVie, Glycomimetics, Novartis, and Blueprint MedicinesData Safety Monitoring Board: Daiichi-SankyoOther Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2026. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Learn More about Peter at: https://www.linkedin.com/in/petertmclaughlin/ and his work at : https://blueskyhypnosis.com Follow him on Social Media: Twitter: https://x.com/PetMcLaughlin IG: https://www.instagram.com/thepetermclaughlin/ YT: https://www.youtube.com/@BlueSkyHypnosis Show Notes   

In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Reuben Kapur and Robert Campbell on their latest articles published in Blood. This episode highlights two groundbreaking studies exploring how inflammation drives serious blood and immune-related diseases. In the first interview, Dr. Kapur discusses how inflammatory bowel disease (IBD) can both promote and worsen clonal hematopoiesis of indeterminate potential (CHIP), with large-scale human data and mouse models identifying REF1 as a key mediator and potential therapeutic target. The second segment features Dr. Campbell, who explains how heme released during malaria infection activates platelet mTOR signaling, intensifying cerebral malaria and suggesting new avenues for platelet-targeted treatments. Together, the conversations reveal how inflammatory pathways and immune signaling contribute to disease progression while opening the door to novel precision therapies. 

Dr. Robert Soiffer took an interest in medicine at an early age when he played a physician in his first-grade play.  Today, he is a leading physician, researcher, and teacher at Dana-Farber Cancer Institute, a world leader in oncology.  In this episode, Dr. Soiffer describes the incredible pace of change in the field of cancer research and treatment and the detection tools and cures that are right around the corner.  He also reflects on how he maintains a positive and optimistic outlook despite the many times he's forced to deliver terrible news to patients and families.  While he tries hard not to bring these tough times home with him, he also stresses the importance of keeping his humanity and treating his patients and their families as people, not just statistics.     Chapters:  02:29 Dana-Farber's Special Mission  Dr. Soiffer discusses what makes Dana-Farber Cancer Institute unique, emphasizing its focus on cancer patients and the common purpose among all staff.   05:50 Evolution of Cancer Treatment  This segment details the seismic shift in cancer treatment over the past 40 years, from nonspecific chemotherapy to targeted therapies focusing on specific mutations.   10:25 Bone Marrow Transplants and Graft vs. Leukemia  Dr. Soiffer delves into the history of bone marrow transplants, highlighting the Nobel Prize-winning work of E. Donald Thomas and the intriguing concept of graft versus leukemia effect.   15:02 The Role of Medical Education and Mentoring  This chapter emphasizes the critical role of medical education and mentoring in shaping the future of medicine, drawing from Dr. Soiffer's experience as chief medical resident and mentor. He discusses the mutual learning process between experienced physicians and younger generations, and the importance of continuous learning.  19:50 Personal Impact of Oncology Work  Dr. Soiffer reflects on the emotional challenges of his work, balancing optimism with realism and honesty while treating patients facing life-threatening situations. He discusses the difficulty of compartmentalizing emotions and the importance of maintaining humanity and connection with patients and their families, even when outcomes are not positive.  24:57 The Value of Clinical Trials  This chapter explains the critical role of clinical trials in advancing cancer treatment, from early-stage phase I trials to comparative studies. Dr. Soiffer describes patients participating in these trials as brave pioneers, highlighting how targeted, immune, and cellular therapies would not exist without their contributions.  28:39 Global Collaboration in Medicine  Dr. Soiffer discusses the extensive global collaboration in medical and scientific fields, emphasizing the shared mission to develop therapies for suffering patients.   35:33 Future of Cancer Treatment and Prevention  Looking ahead, Dr. Soiffer predicts less toxic and more precise cancer treatments with improved therapeutic ratios, focusing on overcoming resistance and early detection. He discusses the potential of preventing progression to full-blown malignancy through early intervention and the growing understanding of germline predispositions to cancer.  41:26 Conclusion and Call to Optimism  The episode concludes with Bill Burke thanking Dr. Soiffer for his time and invaluable insights, highlighting the rapid pace of change and innovation in cancer research. He also expresses hope and optimism for the future of cancer care. 

I am very excited to launch a very special series for Jake's Take with Jacob Elyachar Podcast. May is Jewish American Heritage Month (JAHM), which annually celebrates the history, culture, and contributions of Jewish Americans to the United States.  There are no words to describe how ecstatic I am to welcome back Ethan Zohn for a third time! Ethan became a household name when he first appeared on Survivor: Africa, the third season of the legendary US reality TV competition. He won seven challenges and the title of “Sole Survivor.” He appeared on Survivor: All-Stars, where he won four challenges but lasted only 21 days, and returned to compete in the milestone season Survivor: Winners at War, where he only won one challenge and lasted 35 days.  Since Survivor, Ethan has become an influential social entrepreneur. With a portion of his Survivor: Africa winnings, he co-founded Grassroot Soccer (GRS). GRS is an adolescent health organization that harnesses the power of soccer to provide young people with the essential information, services, and mentorship they need to lead healthier lives. Since its inception, GRS has expanded to 60 countries in Africa and worldwide, has graduated 13 million youth, and has worked with scores of public—and private-sector partners.  He also raised his voice to fight cancer.  Cancer-free since 2012, Ethan Zohn has been a voice for fighters, survivors, and caregivers of all ages, even chronicling the gritty details of his entire cancer experience for People Magazine. While undergoing treatment, he ran and finished the New York City and Boston marathons to help spread messages of hope and resilience to the world.  Ethan is a champion for investment in new medical research and technology. He is an advisor to numerous hospitals and foundations, such as Cancer Buddy, the Leukemia and Lymphoma Society, and Memorial Sloan Kettering.  As demonstrated by his charitable work, tzedakah, and community involvement, Ethan believes that Jewish values can achieve a better and healthier world. His inspiration to help heal the world stems from being taught at an early age the importance of community, a connection to the Jewish faith, and the preservation of Israel.  Ethan shares his deep bond to Judaism, his connection to the Jewish community, and his relationship with Israel by partnering with Jewish organizations that do critical work worldwide, such as BBYO, the Jewish National Fund, and Maccabi USA.  On this edition of The Jake's Take with Jacob Elyachar Podcast, Ethan Zohn gave his take on Survivor 50, previews Grassroot Soccer's 25th anniversary, and how Grassroot Soccer is going to play a role with the World Cup coming to North America.Become a supporter of this podcast: https://www.spreaker.com/podcast/jake-s-take-with-jacob-elyachar--4112003/support.

Leukemia expert Dr. Maximilian Stahl speaks with Dr. Eric Winer about all things leukemia including genetic disposition, environmental factors and what new research is revealing. Yale Cancer Center Visit: https://medicine.yale.edu/cancer/ Email: canceranswers@yale.edu Call 203-785-4095

In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Alexis Thompson, former ASH president, on her latest article published in Blood. Dr. Thompson discusses "Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia." She explains transfusion-dependent β-thalassemia (TDT) requires rigorous, lifelong transfusion therapy and iron chelation to manage iron overload. Dr. Kwiatkowski and colleagues discuss the long-term efficacy and safety of this gene therapy in 63 patients with TDT, documenting sustained transfusion independence for up to 10 years and a safety profile consistent with that of myeloablative autologous transplantation.

TODAY ON THE ROBERT SCOTT BELL SHOW: Jonathan Emord, Whole Foods Pulls Homeopathics, Government Cannot Heal Us, Fauci Email Manager Charged, Gore's New Ice Age, Iowa Vaccine Ban Bill, Florida Vax Mandates, Chemicals in New Babies Blood, Childhood Leukemia Link, Autism Committee Meets, Castor Equi, and MORE! https://robertscottbell.com/jonathan-emord-whole-foods-pulls-homeopathics-government-cannot-heal-us-fauci-email-manager-charged-gores-new-ice-age-iowa-forced-vaccine-ban-bill-florida-vaccine-mandates-chemicals-in-new-ba/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Francesco Forconi and Bin Guo on their latest articles published in Blood. Dr. Guo shares insights from "Nucleoplasmic ZNF467 condensates boost hematopoietic stem cell engraftment via ICAM1-mediated mechanical reprogramming". The findings establish biomechanical regulation as an important determinant of stem cell identity and reveal new strategies for engineering stem cells with enhanced regenerative capacity. Then, Dr. Forconi discusses "DC-SIGN binding to the surface immunoglobulin oligomannose-type glycans promotes follicular lymphoma cell adhesion and survival". Persistent, low-level BCR engagement by DC-SIGN enables FL tissue retention and survival while avoiding the deleterious proapoptotic consequences of stronger, conventional antigen-driven BCR signaling. These findings help explain how FL cells exploit their microenvironmental niche.

The race is on for The Leukemia and Lymphoma "Visionary Of The Year" and Kati Grasmick and Andy Kobus joined Nestor at Koco's Pub on the Maryland Crab Cake Tour to discuss the annual event being held at the Pendry on June 6th to support fundraising and awareness for cancer patients locally. The post Kati Grasmick and Andy Kobus bring LLS Visionary Of The Year events on June 6th into local focus for fundraising first appeared on Baltimore Positive WNST.

In this episode, we review the high-yield topic of ⁠ ⁠⁠Hairy Cell Leukemia (HCL)⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

What does it really take to develop new treatments for pediatric cancer?In this episode of Game Over: c*ncer, we sit down with Dr. Elliot Stieglitz, a leading pediatric hematologist-oncologist and researcher at UCSF, to break down the reality behind pediatric cancer research, clinical trials, and breakthrough treatments for rare diseases like juvenile myelomonocytic leukemia (JMML).JMML is a rare and aggressive form of childhood leukemia affecting just 50–100 children per year in the United States, yet it presents some of the biggest challenges in diagnosis and treatment. Historically, survival rates have been low, and treatment options have been limited.Dr. Stieglitz shares how his groundbreaking research into RAS gene mutations and DNA profiling has:Revolutionized how JMML is diagnosedEnabled faster, more accurate testing worldwideHelped doctors predict which patients need aggressive treatmentOpened the door to targeted therapies and clinical trialsWe also dive into the reality of medical research timelines, why innovation takes years, and how nonprofit funding plays a critical role in bringing life-saving treatments to children.If you've ever wondered how pediatric cancer breakthroughs actually happen—or what it takes to move from research to real-world impact—this episode is for you.----------------------------------Connect with Dana: https://www.linkedin.com/in/danaknichols/Connect with Val: https://www.linkedin.com/in/valerie-solomon/Upcoming Ckc Events: https://cannonballkidscancer.org/category/make-an-impact/events/----------------------------------Podcast Produced by Hi Hello Labs: Website: https://www.hihellolabs.com/

Throughout his career, RJ Moore has led some of the largest wealth management firms in the industry through challenging times. He's held CEO positions at Cetera Financial Group, Legal & General Investment Management America, and ABN AMRO La Salle Bank. He's also the former president of LPL Financial. But perhaps his biggest challenge came during the summer 2023, when he was diagnosed with Stage IV melanoma. His doctor called, saying the skin cancer had spread to much of his body, including his brain, heart, lungs, the lymphatic system and liver. When he got the news, RJ made a conscious decision not to view the cancer as something he had to fight or battle. What if the adversity could become a turning point for gratitude, perspective and a deeper connection with others? In this episode of The Healthy Advisor, host Diana Britton speaks with RJ Moore, partner at Private Advisor Group, about his unexpected journey with melanoma. He shares how the diagnosis reshaped his view of life, leadership, and daily priorities.  He discusses:     The moment RJ learned his melanoma had spread rapidly throughout his body and vital organs     How meditation and breathing practices helped him stay calm after hearing he had months to live     Why RJ replaced the idea of “fighting cancer” with a mindset centered on grace and gratitude     The impact of support from family, friends and the advisory community during treatment     Practical ways advisors can stay present and appreciate everyday moments in busy lives Resources: Listen to The Healthy Advisor on Wealth Management Subscribe and listen to The Healthy Advisor on Apple Podcasts Subscribe and listen to The Healthy Advisor on Spotify Connect With RJ Moore: LinkedIn: RJ Moore Website: Private Advisor Group rj.moore@pagria.com  Connect with Wealth Management: Wealth Management LinkedIn: Diana Britton diana.britton@informa.com LinkedIn: Informa LinkedIn: Wealth Management About Our Guest: RJ Moore is a Partner at Private Advisor Group and helps lead the overall governance of the firm. He brings over 30 years of experience in financial services to the team. Prior to joining Private Advisor Group, RJ has held CEO positions at Cetera Financial Group, Legal & General Investment Management America, and of ABN AMRO La Salle Bank. He was also President of LPL Financial. RJ earned a Master of Business Administration in Finance and Financial Management Services from Northwestern University – Kellogg School of Management and a Bachelor of Arts of Business Administration from the University of Texas. He is the former chair of Invest in Others and has also served on the boards of The Chicago Shakespeare Theater, Chicago Historical Society, and Jane Addams Hull House. In addition, he is an ardent supporter of The Leukemia & Lymphoma Society and the Navy Seal NSW Family Foundation. In 2024, RJ was honored at the AIM Steps Against Melanoma Foundation walk. RJ lives in San Diego with his wife, Sarah. Outside of work, he enjoys visiting family and friends across the U.S., spending time in Palm Springs, and reading Historical Biographies. RJ Moore is solely an investment advisor representative of Private Advisor Group, and not affiliated with LPL Financial.

What if the reason you feel stuck has nothing to do with willpower? Hypnotherapist Peter McLaughlin breaks down the truth about the subconscious mind and how it impacts your habits, relationships, and healing. After being diagnosed with Leukemia and Lyme disease, he was told he had 10 years to live. So Peter began exploring the mind-body connection, and what he discovered not only changed his life, but became his life’s work.

In this week's episode, Blood podcast editor Laurie Sehn interviews Drs. Edward Cliff on his latest research published in volume 147 issue 14 of Blood. Dr. Cliff discusses "Global access to commercial CAR T-cell therapies: a cross-sectional study of health technology assessment across the G20 countries" which maps the mismatch between innovation and implementation across high-income and selected-upper-middle-income countries for US Food and Drug Administration–approved products and indications. 

Longevity, Success, Healthy Living, and Nutrition Made Simple Join Our Health Club Community FREE https://www.drasa.com/health-club   Visit Us At Our Health Club Retreats https://www.drasa.com/retreats/ It's Dr. Asa Here... Ask Me Your Question! Text Me: 407-255-7076 Call Me: 888-283-7272

Bill Berlin is a flight nurse and serves in the USAF. His daughter is currently battling Leukemia and Bill was kind enough to come on to the podcast to talk about what this journey has taught him about being a health care provider. Listener discretion is advised.

What if the reason you feel stuck has nothing to do with willpower? Hypnotherapist Peter McLaughlin breaks down the truth about the subconscious mind and how it impacts your habits, relationships, and healing. After being diagnosed with Leukemia and Lyme disease, he was told he had 10 years to live. So Peter began exploring the mind-body connection, and what he discovered not only changed his life, but became his life’s work.

Send us Fan MailMorning Prayer (Thank You LORD; Leukemia; Unborn Children; Family)Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peaceaimingforjesus.comYouTube Channel https://www.youtube.com/@aimingforjesus5346Instagram https://www.instagram.com/aiming_for_jesus/Threads https://www.threads.com/@aiming_for_jesusX https://x.com/AimingForJesusTik Tok https://www.tiktok.com/@aiming.for.jesus

In this week's episode, Blood podcast editor Dr. James Griffin interviews authors Drs. Steffen Boettcher and Robert Zeiser on their recent publications in Blood. Dr. Boettcher discusses "Bone marrow failure, somatic rescue by p53 inactivation, and enhanced leukemogenesis in germ line ERCC6L2 disease", which provides insights to disease evolution by demonstrating that p53 loss can rescue BMF phenotypes caused by biallelic mutations in ERCC6L2, but at the cost of profound genome instability, increasing DNA damage and leading to the onset of aggressive erythroid leukemia. Dr. Zeiser discusses "Gastrin for the treatment of acute graft-versus-host-disease of the stomach", which delineates the protective role of gastrin in aGVHD of the stomach in mice and patients and provides a rationale for therapeutic use of pentagastrin in a clinical trial for patients with aGVHD.

Guest Dr. John Wingard and host Dr. Davide Soldato discuss JCO article, "Randomized Non-inferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem Cell Transplant and Acute Leukemia Patients," the reason behind the trial, its design, methodology, results, and the implications for future dietary approaches in hematology. LINK TO FULL TRANSCRIPT

"God doesn't always remove the suffering—He enters into it with us.” In this first half of our conversation, Tom and Heather Snyir share the story of their daughter, Katie Rae—a creative, joyful teenager who made everyone around her feel like they were her best friend.Katie was diagnosed with leukemia at just four years old.  Tom and Heather share what it was like to navigate months of treatment, a bone marrow transplant, and the gift of more than a decade of remission.Then, as a teenager, Katie was diagnosed with glioblastoma, an aggressive and deadly form of brain cancer. In this episode, Tom and Heather begin sharing what that journey looked like for their family and how they walked through those difficult days together until Katie went to Heaven.Throughout this conversation, you'll hear how their faith was stretched and sustained—not through easy answers, but through God's presence in the middle of uncertainty.Resources & Mentions Tom Snyir's book: Branches of Grace: Devotions from the Front Lines of Faith - Available HERE.  Coming NextIn next week's episode, Tom and Heather share what life has looked like since Katie went to Heaven. We talk about grief in everyday life, how people respond to loss, and Tom shares more of his personal journey through PTSD, depression, and finding hope.I would love to hear your thoughts on the show. Click here to send me a message! (Though I read every message, I am unable to respond through this format.) ** IMPORTANT** - All views expressed by guests on this podcast are theirs alone, and may not represent the Statement of Faith and Statement of Beliefs of the While We're Waiting ministry.  We'd love for you to connect with us here at While We're Waiting! Click HERE to visit our website and learn about our free While We're Waiting Weekends for bereaved parentsClick HERE to learn more about our network of While We're Waiting support groups all across the country. Click HERE to subscribe to our YouTube channelClick HERE to follow our public Facebook pageClick HERE to follow us on Instagram Click HERE to follow us on Twitter Click HERE to make a tax-deductible donation to the While We're Waiting ministryContact Jill by email at:  jill@whilewerewaiting.org 

In this week's episode, we continue our journey through the relapsed/refractory myeloma space, with a focus on the role of bispecific T-cell engagers. Another incredibly important conversation that is so important in the current treatment landscape and one that you don't want to miss.If you haven't done so already, be sure to check out our CAR T episode.Content:- What are bispecific T-cell engagers? - How are they different than CAR T? - A discussion of the pivotal MajesTEC-3 trial (NEJM 2025) - What are key side effects?- How to sequence CAR T vs. bispecific T-cell engagers? ** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

One Life To Live: My Journey Through Health, Healing, And Faith -Surviving Stage 4 Cancer by Barton H Dunn https://www.amazon.com/One-Life-Live-Journey-Surviving/dp/B0F1JYZV75 What would you do if you were told you had only months to live? In One Life to Live, Barton H. Dunn shares his extraordinary true story of faith, resilience, and the power of miracles. What started as a simple doctor’s visit quickly turned into a life-changing diagnosis – Stage 4 A.L.L. Leukemia. Facing impossible odds, Bart embarked on a grueling journey through chemotherapy, radiation, and ultimately a life-saving bone marrow transplant from his identical twin brother. This inspiring memoir not only chronicles his battle with cancer but also highlights the profound spiritual encounters that shaped his healing process. Through each hardship – from the devastation of his diagnosis to the miraculous moments of divine intervention – Bart’s unwavering faith carried him forward. Part personal reflection, part spiritual testimony, this book is a beacon of hope for anyone facing life’s toughest battles. Whether you’re fighting illness, walking alongside a loved one, or simply seeking inspiration in times of adversity, One Life to Live will uplift your spirit and remind you that miracles still happen. Join Bart on his journey through health, healing, and faith – a testament to the incredible strength found in hope, prayer, and the unwavering belief that God is always listening.

On this Make a Difference Minute, I'm joined by Jessica Bulak, a mother navigating every parent's worst fear. Her son, Miller, was diagnosed with B-cell lymphoblastic leukemia on June 14, 2025, just before his second birthday. What started as a low-grade fever and bruising quickly turned into a life-changing diagnosis and a three-year treatment plan at St. Jude Children's Research Hospital. Jessica shares what that moment was like, how she recognized the early signs, and how she's learned to face an overwhelming journey one step at a time. With faith, support, and the care of St. Jude, she's focusing on hope while walking a very long road ahead. This community spotlight is brought to you by Premier Structures, Inc., proudly supporting stories and the people who make our communities strong. Real stories. Real people. Real impact. News That Unites!™️

In this episode, Blood Associate Editor Dr. Jason Gotlib discusses the Review Series "The New Wave of Targeted Therapeutics for MPN's", with authors Drs. Stefan Constantinescu, Ann Mullally, and Marina Kremyanskaya. This Review Series covers 3 areas where exciting advances are occurring. Dr. Constantinescu discusses “Next-generation JAK inhibitors in the treatment of myeloproliferative neoplasms” which describes how new ways to switch off JAK signaling are delivering a suite of new small-molecule drugs with potential. Dr. Mullally discusses “Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis” which reviews the biology of calreticulin mutations in myelofibrosis and ET and how multiple different modalities can be brought to bear against this mutant surface protein, including monoclonal antibodies, bispecific T-cell engagers, and cellular and vaccine therapies. Dr. Kremyanskaya discusses “Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis” which outlines the major recent progress being made in controlling excessive erythropoiesis through pharmacological modulation of iron metabolism.

In this week's episode, we take a practical dive into the relapsed/refractory myeloma space, with a focus on the role of CAR T therapy for relapsed/refractory. In our next episode, we will continue on with a discussion on bispecific agents! This is a conversation that is so important in the current treatment landscape and one that you don't want to miss. Content:- What are treatment options for patients with relapsed/refractory multiple myeloma (R/R MM)? - What is CAR T therapy? And what role does it play in R/R MM?- What are the available options for CAR T for R/R MM?- What are the toxicity profiles of available agents? - How to choose between the options?** This episode is sponsored by The Lymphoma, Leukemia and Myeloma Congress! To learn more and register for the meeting, visit llmcongress.com/podcast! Be sure to use our special TFOC code TFOC40 to save 40% off registration. ** Want to review the show notes for this episode and others? Check out our website. Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Youtube

A highly respected patient advocacy organization with a trusted identity and decades of impact made a bold decision to change – the reasons behind this decision matter for every organization. For many advocacy leaders, brand identity is deeply tied to trust and recognition. But as science evolves and patients' needs become more complex, organizations must ask themselves: are we reaching all the patients we're meant to serve?In this episode of Patient Advocacy Voices, host Eric Racine is joined by Anders Kolb, President and CEO of Blood Cancer United, alongside returning co-host Elizabeth Franklin of Sanofi. Together, they explore one of the most difficult and necessary decisions an organization can make: transforming an already strong identity to better serve patients. What may look like a simple rebrand is, in reality, a story of leadership, courage, and a deep commitment to patients. Dr. Kolb shares both his professional journey as a pediatric oncologist and his personal connection to blood cancer. He reveals how data, listening, and lived experience uncovered a critical gap: too many patients did not see themselves reflected or served by the organization. This resulted in a strategic change from the Leukemia & Lymphoma Society to Blood Cancer United, a name and movement designed to be more inclusive, more representative, and expand access and support for everyone affected by blood cancer.In this episode, you'll gain insights on:How to recognize when your organization's mission has outgrown its brandHow to make a bold, forward-looking decision by reading the right signalsWhy inclusive language helps more patients feel seen, supported, and connectedHow to tie culture, strategy, and success metrics around real patient impact Ways to lead a large-scale organizational change This episode reveals how proactive leadership decisions can transform an organization to expand its impact, remove barriers, and ultimately connect more patients to the support they need when it matters most.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Alexander Bick and Jorge Cortes on their latest papers published in Blood. Dr. Cortes, the current EIC of Blood Global Hematology discusses "Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial" wherein the planned secondary analysis showed a further efficacy advantage and a consistently favorable safety profile for asciminib relative to investigator-selected TKIs, especially second-generation TKIs. Dr. Bick discusses "Increased prevalence of clonal hematopoiesis in children with sickle cell disease" where targeted sequencing for CH mutations in 2318 children with SCD and 2957 controls and found that children with SCD have a higher prevalence of CH, and majority of CH cases identified were very small “micro-CH” clones, more work is needed to define the clinical significance of these clones.

In this week's episode of the Blood podcast, editor Dr. James Griffin interviews Drs. Christian Gorzelanny and Rebecca Leaf on their latest articles published in this week's issue of Blood. Dr. Gorzelanny discusses compelling evidence for a new mechanism that amplifies their proinflammatory actions in "Lipid nanotubes unmask neutrophils for complement attack", demonstrating the pathological role of this process in a range of inflammatory disorders in order to stimulate intense study of how to regulate nanotube formation for therapeutic benefit. In "Immune thrombocytopenia in patients treated with immune checkpoint inhibitors" Dr. Leaf and colleagues define the incidence, clinical features, and outcomes of ICI-induced immune thrombocytopenia. Showing that ICI-induced immune thrombocytopenia is associated with excess mortality, these data should provide an impetus to greater recognition and to protocolization of effective interventions.

Thank You, God, for One More Day: Claudine Contois on Family, Grit, Faith, and a Life Fully Lived | Conversations with a Chiropractor Some conversations stop being content and become something closer to a keepsake. This is one of those. In this episode of Conversations with a Chiropractor, Dr. Stephanie Wautier sits down with Claudine Contois for a conversation that moves through nearly nine decades of memory, family, hardship, humor, survival, and love. Since this interview was recorded, Claudine has passed away. Her presence is felt deeply throughout this episode, and for those who would like to read more about her life, her obituary can be found here: https://www.fassbenderswansonhansen.com/obituaries/Claudine-Ann-Contois?obId=47520137#/obituaryInfo What makes this episode special is how fully Claudine shows up as herself. She talks about growing up in Kingsford between Italian and Swedish family roots, her deep bond with her younger brother, and the people who shaped her early life. She shares what it meant to raise four boys, leave an abusive marriage to protect them, build a second marriage that lasted more than 50 years, and create a life full of horses, snowmobiles, camping trips, card games, and unforgettable family stories. She also speaks with unusual honesty about the final chapter of her life. After a sudden leukemia diagnosis, Claudine talks openly about fear, faith, readiness, family care, and her one simple wish, not to go alone. Even in the heaviest moments, she remains unmistakably herself: practical, funny, blunt, loving, and grateful for one more day. This is a conversation about caregiving, resilience, marriage, mortality, and the memories that outlast everything else. It is also, now, a remembrance of a woman whose strength, humor, and warmth are all over every minute of it. In This Episode, Discover Claudine's childhood in Iron Mountain and Kingsford, shaped by Italian and Swedish roots Her close relationship with her brother and the family stories that stayed with her How she left an abusive marriage and rebuilt life with four boys Meeting her second husband through dancing, and building a marriage that lasted decades Her adventurous life as a mother, from horses and camping to snowmobiles and lake memories Caregiving for her parents and husband, and what those years taught her Her sudden leukemia diagnosis and the honesty with which she faced it Why memory, family presence, faith, and gratitude became the center of her final season Stay Connected & Explore Follow Conversations with a Chiropractor on YouTube: http://www.youtube.com/@ConversationswithaChiro Follow Dr. Stephanie on Facebook: https://www.facebook.com/wautierwellness Email for show-related inquiries and sponsorships: drstephaniewautier@yahoo.com In Memory of Claudine Contois Read Claudine's obituary here: https://www.fassbenderswansonhansen.com/obituaries/Claudine-Ann-Contois?obId=47520137#/obituaryInfo Credits Podcast production by Brand|Sound. Start your podcast journey by emailing brandsoundpodcasts@gmail.com. Chapters 00:00 Before we begin, a note about Claudine 00:39 Introduction to Conversations with a Chiropractor 01:18 Meet Claudine and her early family roots 03:45 Her brother, childhood memories, and family closeness 05:25 Leukemia diagnosis and being told time was short 06:20 Raising four boys and living full-out with them 09:20 Fear, seizures, and not wanting to be alone 10:00 Leaving an abusive marriage to protect her children 12:00 Meeting her second husband through dancing 14:00 Marriage advice, communication, and caregiving strain 18:10 Horseback trips, camping stories, and Whitefish Falls 21:00 Raccoons, pigs, and Claudine's farm toughness 25:00 The sudden turn in her health and the ER visit 27:20 Faith, readiness, and gratitude for one more day 28:15 Caring for her parents at the end of their lives 30:10 Cribbage, late nights, and family routines 33:00 Walkers, wheelchairs, and learning to be cared for 39:00 Nicknames, ancestry, and family identity 42:00 Wine, farm life, and old family traditions 45:00 The fun she brought to other people's lives 49:00 Facing the ending, and what comes next 50:45 Closing condolence for Claudine and her family

In this week's episode, Blood editor Dr. Laura Michaelis interviews authors Drs. Marion Falabrègue and Ajai Chari on their papers published in volume 146 issue 24 of Blood. The work of Dr. Falabrègue and colleagues in "Intestinal hepcidin overexpression promotes iron deficiency anemia and counteracts iron overload via DMT1 downregulation" indicates that iron absorption from the apical surface of enterocytes can be modulated through manipulation of the hepcidin-DMT1 interaction, opening new avenues for research and therapeutic manipulation. "Talquetamab plus daratumumab in multiple myeloma" features a phase 1b/2 trial of 65 heavily pretreated patients with MM, where Chari et al combined daratumumab and talquetamab, a GPRC5D-targeting bispecific antibody, reporting depletion of CD38-expressing regulatory T cells following daratumumab and impressive efficacy, with an 80% overall (57% complete) response rate and median progression-free survival of 23.3 months. This regimen is now being evaluated in a phase 3 trial. 

When Megan Gilmour's son was 10 years old, he spent nearly two years in isolation at the Sydney Children's Hospital. The months he missed at school didn't just affect him academically. Megan, her daughter and her husband all relocated from Canberra to be with Darcy in Sydney as he underwent life-saving medical treatment, and lived at hospital.Over his many months in hospital, Darcy missed a lot of school. What worried Megan wasn't just that he was falling behind academically, it was his loneliness and the way he was losing connection to his friends and his community.Over time Megan watched how Darcy's sense of belonging vanished because he wasn't physically at school.So along with two other mums she met through the Sydney Children's Hospital, Megan decided to do something about it.Not just for the kids who are missing out of school because they are in hospital, but for the growing number of kids who are away from school for a whole host of reasons.Megan is the CEO and co-founder of Missing School, and she was the 2025 ACT Australian of the Year.This episode of Conversations was produced by Meggie Morris. Executive Producer is Nicola Harrison.It explores chronic illness, sick kids, school non attendance, school refusal, my kid doesn't want to go to school, young carers, neurodiverse children, autism, ADHD, AuDHD, learning difficulties, childhood cancer, blood disorders, lonely children, invisible siblings, parenting, motherhood, online learning, COVID, digital schooling, bone marrow transplant.To binge even more great episodes of the Conversations podcast with Richard Fidler and Sarah Kanowski go the ABC listen app (Australia) or wherever you get your podcasts. There you'll find hundreds of the best thought-provoking interviews with authors, writers, artists, politicians, psychologists, musicians, and celebrities.

Chronic lymphocytic leukemia is the most common leukemia in adults, yet its earliest warning sign often hides in plain sight. Monoclonal B cell lymphocytosis, or MBL, affects millions of adults who may never know they carry this precursor to CLL. In this episode of Tomorrow's Cure from Mayo Clinic, host Cathy Wurzer talks with hematologist Dr. Sameer Parikh and researchers Dr. Susan Slager and Dr. Gerald Marti about how MBL was discovered, what it reveals about inherited risk, and why it matters for infections, second cancers and long term health. The conversation explores how large population studies at Mayo Clinic, advanced genomics, and emerging tools like artificial intelligence and liquid biopsy could change when and how CLL is found, monitored and treated. Listeners will also hear candid discussion about ethics, anxiety and watchful waiting, and how Mayo Clinic's PreCure initiative is rethinking cancer prevention clinics for people living with early warning signs in their blood. How to listen and stay connected:• Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode.• Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: ⁠https://mayocl.in/3EcNPNc⁠ Connect with Mayo Clinic:• Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/⁠Follow • Mayo Clinic on Instagram: ⁠https://www.instagram.com/mayoclinic/⁠Follow • Mayo Clinic on X (formerly Twitter): ⁠https://x.com/MayoClinic⁠Follow • Mayo Clinic on Threads: ⁠https://www.threads.net/@mayoclinic

Tony Garcia will talk about his early in life Pediatric Cancer battle which began in 1973 when he was diagnosed with Leukemia  when he was 2 1/2 years old. Tony's treatment finally ended nearly 10 years later in 1983 and since that time he has been doing as well as possible for the past 43 years, as a long term Pediatric Cancer survivor. Now 55 years old, Tony just published his first book (memoir) at the end of January called MY CHILDHOOD CUT SHORT. SURVIVING LEUKEMIA AND FINDING PURPOSE BEOND PAIN. Tony also is involved in supporting Pediatric Cancer patients through fundraising, volunteering, and advocacy work. 

Rich — a leukemia survivor, nurse practitioner, and longtime oncology clinician — to talk about what it's really like to survive cancer, rebuild your life after treatment, and live with long-term side effects.Rich was diagnosed with leukemia at age 28, underwent an allogeneic stem cell transplant at Dana-Farber / Brigham and Women's, and is now a 29-year survivor. His experience as both a patient and provider offers a rare, honest look at cancer survivorship, prostate cancer side effects, sexual health, mental health, and post-traumatic growth.In this conversation, we cover:What it's like to be told you have leukemia in your 20sStem cell transplant and long-term survivalTurning cancer into purpose and becoming an oncology NPCommon prostate cancer side effects (urination, bowel changes, erectile dysfunction)How doctors actually manage these symptomsSexual health after cancer treatmentMental health, grief, and post-traumatic growthHow to rebuild your life after active treatmentThis episode is for patients, survivors, caregivers, and anyone navigating life after a cancer diagnosis.

Amelia Knopp and her father, Ryan Knopp, MD, from Stone Creek Family Physicians in Manhattan, Kansas, join Josh Israel, MD, and Sean Cavanaugh to discuss Amelia's experience with the health care system following a shocking leukemia diagnosis. They share how this diagnosis set Amelia and their family on a journey that they describe as “health care at its best.” Amelia emphasizes the importance of trust in the physician-patient relationship, and how advocating for patients and providing clear communication helps build a better patient experience. Ryan notes how his daughter's experience underscores the importance of value-based care in ensuring that physicians are invested in the relationship with their patients and providing high-quality, accountable care.

She fought what she called a battle with her blood and let the world in on the fight. Tatiana Schlossberg, John F. Kennedy's granddaughter. Her courage in the face of a rare form of Leukemia, and the legacy of public service and family tragedy she sadly now joins. Plus, previewing Zohran Mamdani's history-making inauguration, just after the ball drops tomorrow night, as New York's first Muslim Mayor, and one of the youngest ever to serve. Learn more about your ad choices. Visit podcastchoices.com/adchoices